- Harrison.ai, a Sydney-based business has secured $129 million AUD (about $92.3 million USD) in one of the biggest Series B investments ever for an Australian firm.
- Harrison.ai was founded by Harrison and his brother Dimitry to expand the worldwide capacity of healthcare quality by providing physicians with AI-based solutions.
- Harrison.ai presently has teams in Australia, the United Kingdom, and Vietnam, with ambitions to grow into more countries in the near future.
Biggest Series B investment for Australian firm
Harrison.ai, a Sydney-based business that develops medical devices using AI technology, said today that it has secured $129 million AUD (about $92.3 million USD) in one of the biggest Series B investments ever for an Australian firm.
Horizons Ventures led the round of fundraising, which also featured new investors Sonic Healthcare and I-MED Radiology Network. Existing investors Blackbird Ventures and Skip Capital also returned for the round, bringing Harrison.ai’s total funding to $158 million AUD over the last two years.
Harrison.ai has announced a collaboration with Sonic Healthcare, one of the world’s top medical diagnostics companies, to develop and market novel clinical AI solutions in pathology. The collaboration will begin with histology or the diagnosis of tissue disorders.
This follows another collaboration between Harrison.ai and I-MED Radiology in early 2020 when Annalise.ai was founded to develop AI-based radiology diagnostic assistance solutions.
Providing AI-based solutions
Dr. Aengus Tran, CEO of Harrison.ai, told that he became a doctor in order to help as many people as possible. “As I researched artificial intelligence more, I fell in love with the concept of utilizing AI to benefit more people than I could ever aid in my lifetime.”
Harrison.ai was founded by Harrison and his brother Dimitry in order to expand the worldwide capacity of healthcare quality by providing physicians with AI-based solutions. Dr. Tran stated that Annalise.ai was able to produce its first regulatory-approved product, an AI tool that detects clinical abnormalities on chest X-rays, within 18 months.
The funds will also be used to recruit more AI data scientists and engineers, as well as to develop clinical relationships throughout the world in order to grow into new sectors of healthcare. Harrison.ai claims that their AI-based technology may aid in the diagnosing process in areas where healthcare is scarce.
“COVID has exacerbated the imbalances and problems that the global healthcare system was already facing, particularly in important areas like radiology and pathology,” Dr. Tran added.
Improving healthcare with AI
He also stated that Harrison.ai’s AI-based technology is intended to aid in the scaling of healthcare systems rather than to replace professionals. “With the help of artificial intelligence, we’re providing them the tools they need to make vital healthcare choices swiftly and at scale.”
Harrison.ai presently has teams in Australia, the United Kingdom, and Vietnam, with ambitions to grow into more countries in the near future. According to Dr. Tran, the company’s goods are ready for sale in Australia, the United Kingdom, Europe, and a few Asian nations. The company’s objective is to grow into new areas and treat one million people every day.